China NMPA Inspection - Hebei Union Pharmaceutical CO., LTD. - March 17, 2016

The Baoding Municipal Market Supervision Administration announced on March 17, 2016, a significant enforcement action against Hebei Yimin Pharmaceutical Co., Ltd. The decision, dated March 3, 2016, involved the immediate revocation of the company's "Drug Business License." This severe penalty was imposed due to critical violations of the "Drug Administration Law of the People's Republic of China." Specifically, Hebei Yimin Pharmaceutical Co., Ltd. was found to have engaged in the illegal acquisition of pharmaceutical products through unauthorized channels. Furthermore, the company failed to maintain comprehensive and accurate records of its drug purchases and sales, a fundamental requirement for ensuring product traceability and patient safety. These actions were in direct contravention of Articles 34 and 18 of the aforementioned regulatory framework. Consequently, in alignment with Articles 79 and 84 of the same law, the administrative body determined that the revocation of the company's operating license was the appropriate and necessary action to address the serious non-compliance and protect public health. This announcement serves as a public declaration of the regulatory body's decisive response to the observed breaches.